Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
15 Mar 2022 |
On significant placements in financial instruments |
Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A.
|
Download |
|
14 Mar 2022 |
On significant placements in financial instruments |
Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A.
|
Download |
|
23 Feb 2022 |
On business and financial situation |
The Company releases the full year 2021 financial results presentation
|
Download |
|
23 Feb 2022 |
About corporate governance |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
|
23 Feb 2022 |
On business and financial situation |
The Company releases the press release related to the full year 2021 financial results
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
10 May 2023 |
Announcement of General Shareholders’ Meeting |
ROVI releases the information related to its General Shareholders Meeting
|
Download |
|
10 Apr 2023 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the first quarter of 2023
|
Download |
|
21 Feb 2023 |
Annual Corporate Governance Report |
ROVI releases the 2022 Annual Corporate Governance Report
|
Download |
|
21 Feb 2023 |
Annual Report regarding remuneration of the members of the Board of Directors |
ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
16 Feb 2023 |
On business and financial situation |
The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
05 Jul 2019 |
R&D: new licenses, patents and registered trademarks |
ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia.
|
Download |
|
02 Jul 2019 |
Liquidity contracts and specialists |
Liquidity contract: transactions conducted in the second quarter of 2019
|
Download |
|
26 Jun 2019 |
Información sobre dividendos |
The Company informs about the dividends payment
|
Download |
|
12 Jun 2019 |
Convocatorias y acuerdos de Juntas y Asambleas generales |
ROVI releases the information related to its General Shareholders Meeting
|
Download |
|
08 May 2019 |
Convocatorias y acuerdos de Juntas y Asambleas generales |
ROVI releases the information related to its 2019 General Shareholders Meeting
|
Download |
Pages
